Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
The Placebo Effect01:54

The Placebo Effect

The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes loosely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings.

BMJ open·2026
Same author

Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.

Neuroscience applied·2026
Same author

A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Keep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophrenia.

Schizophrenia research. Cognition·2026
Same author

In memoriam - Robert M. Bilder, Ph.D.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

The Key to Clozapine Mystery May Lie in its Shape.

Schizophrenia bulletin·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Methodological issues in negative symptom trials.

Stephen R Marder1, David G Daniel, Larry Alphs

  • 1The Semel Institute for Neuroscience at University of California, Los Angeles, CA, USA.marder@ucla.edu

Schizophrenia Bulletin
|January 29, 2011
PubMed
Summary
This summary is machine-generated.

This workshop convened experts to address key challenges in designing clinical trials for new schizophrenia medications targeting negative symptoms. Discussions focused on trial design, patient selection, outcome measures, and approval pathways for these difficult-to-treat symptoms.

Related Experiment Videos

Last Updated: Jun 4, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Area of Science:

  • Psychiatry
  • Clinical Pharmacology
  • Neuroscience

Background:

  • Negative symptoms of schizophrenia are a significant unmet medical need, impacting patient functioning and quality of life.
  • Existing pharmacological treatments have limited efficacy for negative symptoms, necessitating improved clinical trial designs.
  • Collaboration between academia, industry, and regulatory bodies is crucial for advancing treatment development.

Purpose of the Study:

  • To identify and discuss critical methodological issues in the design of clinical trials for pharmacological agents targeting negative symptoms in schizophrenia.
  • To foster consensus on best practices for future drug development in this area.

Main Methods:

  • A workshop format involving experts from academia, the pharmaceutical industry, and the US Food and Drug Administration (FDA).
  • Focused discussions on specific design elements including outcome measures, patient eligibility, trial duration, and study design for broad-spectrum or co-medication trials.
  • Evaluation of available instruments for measuring negative symptoms and defining clinically meaningful improvement.

Main Results:

  • Identified the need for a coprimary functional measure in registration trials for negative symptom treatments.
  • Discussed criteria for patient selection, optimal trial durations (proof-of-concept and registration), and study designs for various treatment approaches (broad-spectrum vs. co-medication).
  • Highlighted the strengths and weaknesses of current negative symptom assessment tools and debated the possibility of drug approval for specific symptom subdomains.

Conclusions:

  • Significant methodological challenges exist in developing effective treatments for schizophrenia negative symptoms.
  • Consensus was sought on key design parameters to improve the efficiency and success rate of clinical trials.
  • Further refinement of outcome measures and regulatory pathways is essential for advancing therapeutic options.